GSK press releases
Follow
GSK’s Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression
Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) is the first and only vaccine approved in this population in China.
